National Research (NASDAQ:NRC) Stock Rating Upgraded by Wall Street Zen

National Research (NASDAQ:NRC) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

NRC has been the topic of several other reports. Weiss Ratings raised National Research from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 29th. Citizens Jmp raised their price objective on National Research from $23.00 to $26.00 and gave the company a “market outperform” rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, National Research presently has a consensus rating of “Moderate Buy” and an average price target of $26.00.

National Research Price Performance

NRC stock opened at $19.51 on Friday. National Research has a 52 week low of $11.01 and a 52 week high of $23.68. The firm has a market capitalization of $443.77 million, a P/E ratio of 78.04 and a beta of 0.35. The company has a fifty day simple moving average of $20.44 and a two-hundred day simple moving average of $18.31. The company has a quick ratio of 0.52, a current ratio of 0.52 and a debt-to-equity ratio of 5.48.

National Research (NASDAQ:NRC) last posted its earnings results on Tuesday, July 28th. The company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.46. National Research had a net margin of 4.18% and a return on equity of 142.50%. The firm had revenue of $35.39 million for the quarter, compared to the consensus estimate of $34.90 million.

Institutional Trading of National Research

Several institutional investors and hedge funds have recently modified their holdings of the stock. M&T Bank Corp grew its stake in National Research by 6.4% in the second quarter. M&T Bank Corp now owns 13,608 shares of the company’s stock worth $229,000 after purchasing an additional 823 shares in the last quarter. Sei Investments Co. lifted its holdings in shares of National Research by 1.2% in the 3rd quarter. Sei Investments Co. now owns 76,270 shares of the company’s stock worth $975,000 after buying an additional 900 shares during the period. Russell Investments Group Ltd. grew its position in shares of National Research by 85.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,997 shares of the company’s stock worth $26,000 after buying an additional 921 shares in the last quarter. Invesco Ltd. increased its stake in shares of National Research by 6.3% during the second quarter. Invesco Ltd. now owns 17,368 shares of the company’s stock valued at $292,000 after buying an additional 1,022 shares during the period. Finally, Alliancebernstein L.P. raised its holdings in shares of National Research by 6.3% in the third quarter. Alliancebernstein L.P. now owns 18,499 shares of the company’s stock valued at $236,000 after acquiring an additional 1,100 shares in the last quarter. Institutional investors own 47.26% of the company’s stock.

About National Research

National Research Corp (NASDAQ: NRC), also known as NRC Health, is a healthcare analytics and performance improvement company specializing in patient and employee experience measurement. The company’s cloud-based platform enables healthcare providers to collect real-time feedback through patient satisfaction surveys, post-discharge outreach, and employee engagement tools. NRC Health integrates clinical, operational and financial data to deliver actionable insights that support quality improvement initiatives and value-based care programs.

Since its founding in the early 1990s and headquartered in Lincoln, Nebraska, National Research has expanded beyond its regional roots to serve more than 1,600 hospitals and 12,000 care sites across the United States and Canada.